| Company/Division name | WuXi Advanced Technologies with Iovance |
| Parent company | Wuxi AppTech |
| Type of work | Manufacturing |
| If manufacturing, is the company a contract manufacturer? | Yes |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2024 |
| Year reshoring implemented or to be implemented: | 2024 |
| Domestically, the work will be done: | In-house |
| Country(ies) from which reshored: | China |
| City reshored to: | Philadelphia |
| State(s) reshored to: | PA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | individualised T-cell therapy for adv. melanoma |
| What domestic positive factors made reshoring more attractive? | Manufacturing/engineering joint innovation (R&D) |
